Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Harpoon Therapeutics Inc
(NQ:
HARP
)
23.01
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harpoon Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
September 13, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
September 06, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
September 05, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Earnings Perspective: Return On Capital Employed
March 28, 2023
Via
Benzinga
Harpoon Therapeutics Earnings Perspective: Return On Capital Employed
December 27, 2022
Via
Benzinga
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 05, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
September 04, 2023
Via
Benzinga
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
August 03, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
August 01, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
3 Penny Stocks with Multibagger Potential for the Second Half of 2023
June 26, 2023
If you have patience and a high risk tolerance, here are three penny stocks to watch in 2023 for their multibagger potential.
Via
InvestorPlace
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Short Volatility Alert: Harpoon Therapeutics
April 21, 2023
On Thursday, shares of Harpoon Therapeuti (NASDAQ: HARP) experienced volatile short activity. After the activity, the stock price went down -1.59% to $0.62. The overall sentiment for HARP has been...
Via
Benzinga
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
April 18, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
April 17, 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and...
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
April 10, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
March 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
March 14, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
February 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 17, 2023
Via
Benzinga
Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 15, 2023
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.
Via
Benzinga
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
The 3 Most Undervalued Penny Stocks to Buy in February 2023
February 02, 2023
Here are three penny stocks in emerging sectors that look to be undervalued relative to the consensus price target of analysts.
Via
InvestorPlace
Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 30, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 136% to $2.06 after Ascendant Capital initiated coverage on the stock with a Buy rating and a $3.30 price target.
Via
Benzinga
Why CN Energy Group Shares Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket
January 30, 2023
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares rose 45.4% to $3.52 in pre-market trading after gaining around 7% on Friday. BigBear.AI recently announced a $25 million private placement.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 30, 2023
Via
Benzinga
MarketBeat: Week in Review 12/12 - 12/16
December 17, 2022
A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.